Efficacy and the Safety of Granulocyte Colony-Stimulating Factor Treatment in Patients with Muscular Dystrophy: A Non-Randomized Clinical Trial

Dorota Sienkiewicz, Wojciech Kułak, Bożena Okurowska-Zawada, Grażyna Paszko-Patej, Janusz Wojtkowski, Karolina Sochoń, Anna Kalinowska, Kamila Okulczyk, Jerzy Sienkiewicz, Edward McEachern, Dorota Sienkiewicz, Wojciech Kułak, Bożena Okurowska-Zawada, Grażyna Paszko-Patej, Janusz Wojtkowski, Karolina Sochoń, Anna Kalinowska, Kamila Okulczyk, Jerzy Sienkiewicz, Edward McEachern

Abstract

Introduction: The current standard treatment for patients with Duchenne muscular dystrophy (DMD) involves corticosteroids. Granulocyte colony-stimulating factor (G-CSF) induces the proliferation of satellite cells and myoblasts and, in turn, muscle regeneration. Beneficial effects of G-CSF were also described for skeletal muscle disorders.

Aim: We assessed the safety and effects of using G-CSF to promote muscle strength in patients with DMD.

Materials and methods: Inclusion criteria were as follows: patients aged 5-15 years with diagnosed with DMD confirmed by genetic test or biopsy. Fourteen patients were treated with steroids, and their use was not changed in this study. Diagnoses were confirmed by genetic tests: deletions were detected in 11 patients and duplications in 5 patients. Nineteen 5- to 15-year-old patients diagnosed with DMD-9 were in wheelchairs, whereas 10 were mobile and independent-completed an open study. Participants received a clinical examination and performed physiotherapeutic and laboratory tests to gage their manual muscle strength, their isometric force using a hand dynamometer, and aerobic capacity [i.e., 6-min walk test (6MWT)] before and after therapy. Each participant received G-CSF (5 µg/kg/body/day) subcutaneously for five consecutive days during the 1st, 2nd, 3rd, 6th, and 12th month. Laboratory investigations that included full blood count and biochemistry were performed. Side effects of G-CSF treatment were assessed during each visit. During each cycle of G-CSF administration in the hospital, rehabilitation was also applied. All patients received regular ambulatory rehabilitation.

Results: The subcutaneous administration of G-CSF improved muscle strength in participants. We recorded a significant increase in the distance covered in the 6MWT, either on foot or in a wheelchair, increased muscle force in isometric force, and a statistically significant decrease in the activity of the muscle enzyme creatine kinase after nearly every cycle of treatment. We observed no side effects of treatment with G-CSF.

Conclusion: Our findings suggest that G-CSF increases muscle strength in patients with DMD, who demonstrated that G-CSF therapy is safe and easily tolerable.

Keywords: children; efficacy; granulocyte colony-stimulating factor; muscle strength; muscular dystrophy; safety.

Figures

Figure 1
Figure 1
Study flowchart of granulocyte colony-stimulating factor treatment 1-year therapy of patients with muscular dystrophy. Screening, enrollment, and follow-up.
Figure 2
Figure 2
The treatment protocol schema.

References

    1. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol (2006) 7(10):762–73.10.1038/nrm2024
    1. Manzur AY, Muntoni F. Diagnosis and treatment in muscular dystrophies. J Neurol Neurosurg Psychiatry (2009) 80:706–14.10.1136/jnnp.2008.158329
    1. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry (2013) 84:698–705.10.1136/jnnp-2012-303902
    1. Mendel JR, Llyod-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve (2013) 48(1):21–6.10.1002/mus.23810
    1. Ervasti M, Sonnemann KJ. Biology of the striated muscle dystrophin-glycoprotein complex. Int Rev Cytol (2008) 265:191–225.10.1016/S0074-7696(07)65005-0
    1. Mercuri E, Muntoni F. Muscular dystrophies. Lancet (2013) 381(9869):845–60.10.1016/S0140-6736(12)61897-2
    1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol (2010) 9(1):77–93.10.1016/S1474-4422(09)70271-6
    1. Pane M, Scalise R, Berardinelli A, D’Angelo G, Ricotti V, Alfieri P, et al. Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscul Disord (2013) 23:451–5.10.1016/j.nmd.2013.02.012
    1. Muntoni F. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAD-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th. Neuromuscul Disord (2009) 20:355–62.10.1016/j.nmd.2010.03.005
    1. Stratos I, Rotter R, Elpel C, Mittlmeier T, Vollmar B. Granulocyte-colony stimulating factor enhances muscle proliferation and strength following skeletal muscle injury in rats. J Appl Physiol (1985) (2007) 103(5):1857–63.10.1152/japplphysiol.00066.2007
    1. Hara M, Yuasa S, Shimoji K, Onizuka T, Hayashiji N, Ohno Y, et al. G-CSF influences mouse skeletal muscle development and regeneration by stimulating myoblast proliferation. J Exp Med (2011) 208(4):715–27.10.1084/jem.20101059
    1. Metcalf D. Hematopoietic cytokines. Blood (2008) 111(2):485–91.10.1182/blood-2007-03-079681
    1. Simỡnes GF, Benitez SU, Oliveira ALR. Granulocyte colony-stimulating factor (G-CSF) positive effects on muscle fiber degeneration and gait recovery after nerve lesion in MDX mice. Brain Behav (2014) 4(5):738–53.10.1002/brb3.250
    1. Ruozi B, Belletti D, Bondioli L, De Vita A, Forni N, Vandelli MA, et al. Neurotrophic factors and neurodegenerative diseases: a delivery issue. Int Rev Neurobiol (2012) 102:207–47.10.1016/B978-0-12-386986-9.00009-0
    1. Dumont NA, Rudnicki MA. Targeting muscle stem cell intrinsic defects to treat Duchenne muscular dystrophy. NPJ Regen Med (2016) 1:16006.10.1038/npjregenmed.2016.6
    1. Yen-Mou L, Yi-Jing L. Strength and functional measurement for patients with muscular dystrophy. In: Madhuri H, editor. Muscular Dystrophy. (Vol. 17), Rijeka: InTech; (2012). p. 321–30.
    1. American Thoracic Society. Guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 166(1):111–7.10.1164/ajrccm.166.1.at1102
    1. Eljaszewicz A, Sienkiewicz D, Grubczak K, Okurowska-Zawada B, Paszko-Patej G, Miklasz P, et al. Effect of periodic granulocyte colony-stimulating factor administration on endothelial progenitor cells and different monocyte subsets in pediatric patients with muscular dystrophies. Stem Cells Int (2016) 2016:2650849.10.1155/2016/2650849
    1. Kułak W, Okurowska-Zawada B, Sienkiewicz D, Paszko-Patej G. Cell therapy: a new hope for treatment of cerebral palsy? Prog Health Sci (2012) 2(2):174–80.
    1. Sienkiewicz D, Kułak W, Okurowska-Zawada B, Paszko-Patej G, Kawnik K. Duchenne muscular dystrophy: current cell therapies. Ther Adv Neurol Disord (2015) 8(4):166–77.10.1177/1756285615586123
    1. Hayashiji N, Yuasa S, Miyagoe-Suzuki Y, Hara M, Ito N, Hashimoto H, et al. G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy. Nat Commun (2015) 13(6):6745.10.1038/ncomms7745
    1. Deng B, Wehling-Henricks SA, Villalta Y, Wang S, Tidball JG. IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. J Immunol (2012) 189(7):3669–80.10.4049/jimmunol.1103180
    1. Sakuma T, Yamazaki M, Okawa A, Takahashi H, Kato K, Hashimoto M, et al. Neuroprotective therapy using granulocyte colony-stimulating factor for patients with worsening symptoms of compression myelopathy. Part 1: a phase I and II a clinical trial. Eur Spine J (2012) 21(3):482–9.10.1007/s00586-011-2020-2
    1. Kato K, Yamazaki M, Okawa A, Furuya T, Sakuma T, Takahashi H, et al. Intravenous administration of granulocyte colony-stimulating factor for treating neuropathic pain associated with compression myelopathy: a phase I and IIa clinical trial. Eur Spine J (2013) 22(1):197–204.10.1007/s00586-012-2556-9
    1. Inada T, Takahashi H, Yamazaki M, Okawa A, Sakuma T, Kato K, et al. Multicenter prospective nonrandomized controlled clinical trial to prove neuro-therapeutic effects of granulocyte colony-stimulating factor for acute spinal cord injury: analyses of follow-up cases after at least 1 year. Spine (Phila Pa 1976) (2014) 39(3):213–9.10.1097/BRS.0000000000000121
    1. Niks EH, Aartsma-Rus A. Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther (2017) 17(2):225–36.10.1080/14712598.2017.1271872
    1. Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, et al. Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther (2017) 27:251–9.10.1089/nat.2017.0682

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit